Airdoc

develops AI-based eye-screening technology, including diabetic-retinopathy and broader ophthalmic disease detection, as part of China's growing ophthalmic AI diagnostics base.

Country
China
Commercial AI eye-screening technology
Coverage
CNEUUS
diagnostics-medtech
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
CertificationClass III medical device registration for Airdoc-AIFUNDUS (2.0) from NMPA (April 2025)hkexnews.hk
CertificationClass II medical device registration for AI-FUNDUSCAMERA-P (Model: AI-FD16U) from NMPA (January 2025)hkexnews.hk
CertificationClass II medical device registration for AI-FUNDUSCAMERA-M (AI-FD16M) from NMPA (August 2025)hkexnews.hk
CertificationClass II medical device registration for AI-FUNDUSCAMERA-H (AI-FD16H-VAD) (fundus camera module in August 2024, slit-lamp module in July 2025)hkexnews.hk
Regulatory approvalEU CE MDR certification for Airdoc-AIFUNDUS (1.0) (announced January 2024)eqs-news.com
Regulatory approvalUS FDA certification for Retinal Detection AI (as of end of 2025 Reporting Period)hkexnews.hk
Production siteManufacturing base in the High-Tech Development Zone of Changsha, Hunanhkexnews.hk
CapacityApproximately 100,000 fundus cameras per yearhkexnews.hk
RevenueRMB 173.262 million for the year ended December 31, 2025hkexnews.hk

Independent sources: eqs-news.com · hkexnews.hk

Technologies
NameClusterRisk
AI optical coherence tomography screeningdiagnostics-medtechLow

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.